Warnings and Withdrawals | GenomeWeb

Drugs approved since legislation to speed up the approval process at the US Food and Drug Administration are more likely to have received black box warnings or been withdrawn from the market, according to a new analysis appearing in Health Affairs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.